<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941304</url>
  </required_header>
  <id_info>
    <org_study_id>BUP-201</org_study_id>
    <nct_id>NCT00941304</nct_id>
  </id_info>
  <brief_title>Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain</brief_title>
  <official_title>A Double-Blind, Double-Dummy, Placebo- and Active Controlled Evaluation of the Efficacy, Safety and Tolerability of Buprenorphine HCl Buccal Film in the Treatment of Pain Associated With Third Molar Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioDelivery Sciences International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioDelivery Sciences International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the activity of buprenorphine hydrochloride (HCl)
      buccal film in the treatment of dental pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of Pain Intensity Difference From Baseline to 8 Hours</measure>
    <time_frame>Baseline, 8 hours</time_frame>
    <description>Time-weighted sum of pain intensity difference from baseline to 8 hours (SPID-8) where total score ranges from -80 (worst) to 80 (best) and a higher value indicates greater pain relief. Pain intensity was recorded using an 11-point numeric rating scale (NRS), where 0=none and 10=worst pain imaginable, in response to &quot;What is your pain level at this time?&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief Over 8 Hours</measure>
    <time_frame>8 hours</time_frame>
    <description>Time-weighted sum of total pain relief over 8 hours (TOPAR-8) where total score ranges from 0 (worst) to 32 (best) and higher values indicate greater pain relief. Pain relief (PAR) was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to &quot;How much relief have you had from your starting pain?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Relief and Intensity Differences Over 8 Hours</measure>
    <time_frame>8 hours</time_frame>
    <description>Time-weighted sum of PAR and pain intensity difference (PID) over 8 hours (SPRID-8) where total score ranges from -80 (worst) to 112 (best) and higher values indicate greater pain relief. PAR was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to &quot;How much relief have you had from your starting pain?&quot; PID determined as the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to &quot;What is your pain level at this time?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Relief and Intensity Differences Over 2 Hours</measure>
    <time_frame>2 hours</time_frame>
    <description>Time-weighted sum of PAR and PID over 2 hours (SPRID-2) where total score ranges from 0 (worst) to 8 (best) and higher values indicate greater pain relief. PAR was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to &quot;How much relief have you had from your starting pain?&quot; PID determined as the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to &quot;What is your pain level at this time?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Pain Intensity Difference</measure>
    <time_frame>24 hours</time_frame>
    <description>The maximum PID at any time following dosing determined from the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to &quot;What is your pain level at this time?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Pain Relief</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximum pain relief (PAR) at any time following dosing, recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to &quot;How much relief have you had from your starting pain?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Analgesia</measure>
    <time_frame>8 hours</time_frame>
    <description>Time to onset of analgesia defined as median time to perceptible pain relief if confirmed by experiencing meaningful pain relief from time of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>Duration of analgesia was the median time to use of rescue medication; earliest concomitant medication start time for medications identified as rescue medications from time of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting a Global Rating of Study Drug as &quot;Excellent&quot;</measure>
    <time_frame>8 hours and 24 hours</time_frame>
    <description>Subjects rated the global effectiveness of study drug as poor, fair, good, or excellent, in response to &quot;Overall, how would you rate the study medication you received for pain?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With &quot;Excellent&quot; Investigator Global Rating of Study Drug</measure>
    <time_frame>24 hours</time_frame>
    <description>Investigators rated the global effectiveness of study drug as poor, fair, good, or excellent, in response to &quot;Overall, how would you rate the study medication for this subject?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cognitive Assessment Using CNS-VS</measure>
    <time_frame>Baseline (screening), 2 hours 15 minutes postdose</time_frame>
    <description>Cognition assessed using computer-based CNS Vital SignsÂ® neurocognitive function test (CNS-VS), including symbol digit coding, Stroop test, and shifting attention test to measure cognitive flexibility, executive functioning, processing speed, and reaction time(*). Scores are computed from raw score calculations using the data values of individual subtests. An asterisk denotes that &quot;lower score is better&quot;, otherwise higher scores are better.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Dental Pain</condition>
  <arm_group>
    <arm_group_label>Standard Opioid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone 5-mg oral capsule and 2 buccal placebo films</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, buccal placebo film, and oral placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, buccal placebo film, and oral placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, buccal placebo film, and oral placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo capsule and 2 buccal placebo films</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Single-dose of over-encapsulated oral 5-mg oxycodone capsule</description>
    <arm_group_label>Standard Opioid</arm_group_label>
    <other_name>Oxycodone capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Single-dose of buprenorphine HCl buccal film</description>
    <arm_group_label>High Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_label>Mid Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_label>Low Dose buprenorphine HCl buccal film</arm_group_label>
    <other_name>BEMA Buprenorphine</other_name>
    <other_name>BELBUCA</other_name>
    <other_name>Buprenorphine HCl buccal film</other_name>
    <other_name>Buprenorphine HCl buccal soluble film</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Film</intervention_name>
    <description>Single-dose of placebo buccal film</description>
    <arm_group_label>Standard Opioid</arm_group_label>
    <arm_group_label>High Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_label>Mid Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_label>Low Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Placebo buccal film</other_name>
    <other_name>BEMA placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>Single-dose of oral placebo capsule</description>
    <arm_group_label>High Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_label>Mid Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_label>Low Dose buprenorphine HCl buccal film</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Oxycodone placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  extraction of 2 or more third molars, at least 1 of which must be fully or partially
             impacted in mandibular bone

          -  males or non-pregnant females, aged 18 to 45 years

          -  good general health and capable of providing informed consent

        Exclusion Criteria:

          -  history of substance abuse or dependence

          -  positive urine toxicology screen or alcohol breath test

          -  history of hypersensitivity to or allergy to any study drug

          -  donation of blood within prior 30 days

          -  use of analgesics, caffeine, sedatives, antidepressants, anticoagulant or antiplatelet
             agents within 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Blum, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioDelivery Sciences International</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premier Research Group Limited</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donald P. Bandy, DDS</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research Group Limited</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <results_first_submitted>November 4, 2015</results_first_submitted>
  <results_first_submitted_qc>January 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2016</results_first_posted>
  <disposition_first_submitted>February 24, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>February 24, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 17, 2015</disposition_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
          <description>Buprenorphine hydrochloride (HCl) buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
        </group>
        <group group_id="P2">
          <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
          <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
        </group>
        <group group_id="P3">
          <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
          <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo oral capsule and 2 placebo buccal films</description>
        </group>
        <group group_id="P5">
          <title>Oxycodone 5 mg</title>
          <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis is based on Safety population; all subjects who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
          <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
        </group>
        <group group_id="B2">
          <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
          <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
        </group>
        <group group_id="B3">
          <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
          <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo oral capsule and 2 placebo buccal films</description>
        </group>
        <group group_id="B5">
          <title>Oxycodone 5 mg</title>
          <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="31"/>
            <count group_id="B6" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" lower_limit="18" upper_limit="30"/>
                    <measurement group_id="B2" value="21.0" lower_limit="18" upper_limit="30"/>
                    <measurement group_id="B3" value="21.0" lower_limit="18" upper_limit="27"/>
                    <measurement group_id="B4" value="22.0" lower_limit="18" upper_limit="28"/>
                    <measurement group_id="B5" value="21.0" lower_limit="18" upper_limit="29"/>
                    <measurement group_id="B6" value="21.0" lower_limit="18" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sum of Pain Intensity Difference From Baseline to 8 Hours</title>
        <description>Time-weighted sum of pain intensity difference from baseline to 8 hours (SPID-8) where total score ranges from -80 (worst) to 80 (best) and a higher value indicates greater pain relief. Pain intensity was recorded using an 11-point numeric rating scale (NRS), where 0=none and 10=worst pain imaginable, in response to âWhat is your pain level at this time?â</description>
        <time_frame>Baseline, 8 hours</time_frame>
        <population>Analysis based on intent-to-treat (ITT) population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Difference From Baseline to 8 Hours</title>
          <description>Time-weighted sum of pain intensity difference from baseline to 8 hours (SPID-8) where total score ranges from -80 (worst) to 80 (best) and a higher value indicates greater pain relief. Pain intensity was recorded using an 11-point numeric rating scale (NRS), where 0=none and 10=worst pain imaginable, in response to âWhat is your pain level at this time?â</description>
          <population>Analysis based on intent-to-treat (ITT) population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.016" spread="19.9786"/>
                    <measurement group_id="O2" value="11.867" spread="20.7418"/>
                    <measurement group_id="O3" value="11.282" spread="22.9711"/>
                    <measurement group_id="O4" value="5.283" spread="17.6360"/>
                    <measurement group_id="O5" value="4.290" spread="14.8645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.4739</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.94</ci_lower_limit>
            <ci_upper_limit>12.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.2183</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.81</ci_lower_limit>
            <ci_upper_limit>16.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0809</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>18.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pain Relief Over 8 Hours</title>
        <description>Time-weighted sum of total pain relief over 8 hours (TOPAR-8) where total score ranges from 0 (worst) to 32 (best) and higher values indicate greater pain relief. Pain relief (PAR) was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to âHow much relief have you had from your starting pain?â</description>
        <time_frame>8 hours</time_frame>
        <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pain Relief Over 8 Hours</title>
          <description>Time-weighted sum of total pain relief over 8 hours (TOPAR-8) where total score ranges from 0 (worst) to 32 (best) and higher values indicate greater pain relief. Pain relief (PAR) was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to âHow much relief have you had from your starting pain?â</description>
          <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.274" spread="8.7136"/>
                    <measurement group_id="O2" value="9.858" spread="9.3550"/>
                    <measurement group_id="O3" value="10.500" spread="9.9358"/>
                    <measurement group_id="O4" value="6.392" spread="8.6235"/>
                    <measurement group_id="O5" value="6.242" spread="6.6813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Relief and Intensity Differences Over 8 Hours</title>
        <description>Time-weighted sum of PAR and pain intensity difference (PID) over 8 hours (SPRID-8) where total score ranges from -80 (worst) to 112 (best) and higher values indicate greater pain relief. PAR was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to âHow much relief have you had from your starting pain?â PID determined as the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to âWhat is your pain level at this time?â</description>
        <time_frame>8 hours</time_frame>
        <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Relief and Intensity Differences Over 8 Hours</title>
          <description>Time-weighted sum of PAR and pain intensity difference (PID) over 8 hours (SPRID-8) where total score ranges from -80 (worst) to 112 (best) and higher values indicate greater pain relief. PAR was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to âHow much relief have you had from your starting pain?â PID determined as the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to âWhat is your pain level at this time?â</description>
          <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.290" spread="28.1677"/>
                    <measurement group_id="O2" value="21.725" spread="29.7031"/>
                    <measurement group_id="O3" value="21.782" spread="32.2047"/>
                    <measurement group_id="O4" value="11.675" spread="25.8038"/>
                    <measurement group_id="O5" value="10.532" spread="20.5848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Relief and Intensity Differences Over 2 Hours</title>
        <description>Time-weighted sum of PAR and PID over 2 hours (SPRID-2) where total score ranges from 0 (worst) to 8 (best) and higher values indicate greater pain relief. PAR was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to âHow much relief have you had from your starting pain?â PID determined as the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to âWhat is your pain level at this time?â</description>
        <time_frame>2 hours</time_frame>
        <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Relief and Intensity Differences Over 2 Hours</title>
          <description>Time-weighted sum of PAR and PID over 2 hours (SPRID-2) where total score ranges from 0 (worst) to 8 (best) and higher values indicate greater pain relief. PAR was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to âHow much relief have you had from your starting pain?â PID determined as the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to âWhat is your pain level at this time?â</description>
          <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.339" spread="3.4896"/>
                    <measurement group_id="O2" value="1.533" spread="3.5718"/>
                    <measurement group_id="O3" value="1.056" spread="3.9769"/>
                    <measurement group_id="O4" value="0.850" spread="3.5505"/>
                    <measurement group_id="O5" value="1.484" spread="3.6009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Pain Intensity Difference</title>
        <description>The maximum PID at any time following dosing determined from the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to âWhat is your pain level at this time?â</description>
        <time_frame>24 hours</time_frame>
        <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Pain Intensity Difference</title>
          <description>The maximum PID at any time following dosing determined from the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to âWhat is your pain level at this time?â</description>
          <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="3.50"/>
                    <measurement group_id="O2" value="2.9" spread="3.30"/>
                    <measurement group_id="O3" value="2.8" spread="3.35"/>
                    <measurement group_id="O4" value="1.5" spread="2.50"/>
                    <measurement group_id="O5" value="1.9" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Pain Relief</title>
        <description>Maximum pain relief (PAR) at any time following dosing, recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to âHow much relief have you had from your starting pain?â</description>
        <time_frame>24 hours</time_frame>
        <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Pain Relief</title>
          <description>Maximum pain relief (PAR) at any time following dosing, recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to âHow much relief have you had from your starting pain?â</description>
          <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.59"/>
                    <measurement group_id="O2" value="1.8" spread="1.61"/>
                    <measurement group_id="O3" value="1.9" spread="1.51"/>
                    <measurement group_id="O4" value="1.1" spread="1.36"/>
                    <measurement group_id="O5" value="1.3" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Onset of Analgesia</title>
        <description>Time to onset of analgesia defined as median time to perceptible pain relief if confirmed by experiencing meaningful pain relief from time of study drug administration.</description>
        <time_frame>8 hours</time_frame>
        <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Onset of Analgesia</title>
          <description>Time to onset of analgesia defined as median time to perceptible pain relief if confirmed by experiencing meaningful pain relief from time of study drug administration.</description>
          <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="3.083">Median time to onset of analgesia and/or corresponding 95% confidence interval (CI) could not be determined as more than 50% of the subjects in treatment group failed to activate the stopwatch times within the protocol-specified 8-hour window.</measurement>
                    <measurement group_id="O2" value="2.43" lower_limit="0.617">Median time to onset of analgesia and/or corresponding 95% confidence interval (CI) could not be determined as more than 50% of the subjects in treatment group failed to activate the stopwatch times within the protocol-specified 8-hour window.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="0.750">Median time to onset of analgesia and/or corresponding 95% confidence interval (CI) could not be determined as more than 50% of the subjects in treatment group failed to activate the stopwatch times within the protocol-specified 8-hour window.</measurement>
                    <measurement group_id="O4" value="NA">Median time to onset of analgesia and/or corresponding 95% confidence interval (CI) could not be determined as more than 50% of the subjects in treatment group failed to activate the stopwatch times within the protocol-specified 8-hour window.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="1.017">Median time to onset of analgesia and/or corresponding 95% confidence interval (CI) could not be determined as more than 50% of the subjects in treatment group failed to activate the stopwatch times within the protocol-specified 8-hour window.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Analgesia</title>
        <description>Duration of analgesia was the median time to use of rescue medication; earliest concomitant medication start time for medications identified as rescue medications from time of study drug administration.</description>
        <time_frame>24 hours</time_frame>
        <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Analgesia</title>
          <description>Duration of analgesia was the median time to use of rescue medication; earliest concomitant medication start time for medications identified as rescue medications from time of study drug administration.</description>
          <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="1.667" upper_limit="5.083"/>
                    <measurement group_id="O2" value="2.62" lower_limit="1.783" upper_limit="19.117"/>
                    <measurement group_id="O3" value="4.12" lower_limit="2.067">Corresponding 95% CI for duration of analgesia could not be determined as many subjects did not use rescue medication within 24 hours.</measurement>
                    <measurement group_id="O4" value="1.69" lower_limit="1.583" upper_limit="3.300"/>
                    <measurement group_id="O5" value="2.17" lower_limit="1.683" upper_limit="2.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting a Global Rating of Study Drug as âExcellentâ</title>
        <description>Subjects rated the global effectiveness of study drug as poor, fair, good, or excellent, in response to âOverall, how would you rate the study medication you received for pain?â</description>
        <time_frame>8 hours and 24 hours</time_frame>
        <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting a Global Rating of Study Drug as âExcellentâ</title>
          <description>Subjects rated the global effectiveness of study drug as poor, fair, good, or excellent, in response to âOverall, how would you rate the study medication you received for pain?â</description>
          <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent at 8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="6.7"/>
                    <measurement group_id="O3" value="9.7"/>
                    <measurement group_id="O4" value="6.7"/>
                    <measurement group_id="O5" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Excellent at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="13.3"/>
                    <measurement group_id="O3" value="12.9"/>
                    <measurement group_id="O4" value="3.3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With âExcellentâ Investigator Global Rating of Study Drug</title>
        <description>Investigators rated the global effectiveness of study drug as poor, fair, good, or excellent, in response to âOverall, how would you rate the study medication for this subject?â</description>
        <time_frame>24 hours</time_frame>
        <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With âExcellentâ Investigator Global Rating of Study Drug</title>
          <description>Investigators rated the global effectiveness of study drug as poor, fair, good, or excellent, in response to âOverall, how would you rate the study medication for this subject?â</description>
          <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="13.3"/>
                    <measurement group_id="O3" value="12.9"/>
                    <measurement group_id="O4" value="3.3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cognitive Assessment Using CNS-VS</title>
        <description>Cognition assessed using computer-based CNS Vital SignsÂ® neurocognitive function test (CNS-VS), including symbol digit coding, Stroop test, and shifting attention test to measure cognitive flexibility, executive functioning, processing speed, and reaction time(*). Scores are computed from raw score calculations using the data values of individual subtests. An asterisk denotes that &quot;lower score is betterâ, otherwise higher scores are better.</description>
        <time_frame>Baseline (screening), 2 hours 15 minutes postdose</time_frame>
        <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O2">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O3">
            <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
            <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo oral capsule and 2 placebo buccal films</description>
          </group>
          <group group_id="O5">
            <title>Oxycodone 5 mg</title>
            <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cognitive Assessment Using CNS-VS</title>
          <description>Cognition assessed using computer-based CNS Vital SignsÂ® neurocognitive function test (CNS-VS), including symbol digit coding, Stroop test, and shifting attention test to measure cognitive flexibility, executive functioning, processing speed, and reaction time(*). Scores are computed from raw score calculations using the data values of individual subtests. An asterisk denotes that &quot;lower score is betterâ, otherwise higher scores are better.</description>
          <population>Analysis based on ITT population; all subjects who received study drug and provided at least 1 post-dose assessment.</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cognitive flexibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="17.14"/>
                    <measurement group_id="O2" value="4.0" spread="18.93"/>
                    <measurement group_id="O3" value="-3.2" spread="14.53"/>
                    <measurement group_id="O4" value="7.3" spread="10.81"/>
                    <measurement group_id="O5" value="2.1" spread="17.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Executive functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="17.35"/>
                    <measurement group_id="O2" value="4.1" spread="16.00"/>
                    <measurement group_id="O3" value="-3.0" spread="13.49"/>
                    <measurement group_id="O4" value="7.2" spread="10.83"/>
                    <measurement group_id="O5" value="2.2" spread="17.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Processing speed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="7.64"/>
                    <measurement group_id="O2" value="0.8" spread="6.73"/>
                    <measurement group_id="O3" value="-9.1" spread="14.48"/>
                    <measurement group_id="O4" value="2.8" spread="9.12"/>
                    <measurement group_id="O5" value="1.5" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaction time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="79.82"/>
                    <measurement group_id="O2" value="-19.5" spread="102.16"/>
                    <measurement group_id="O3" value="29.7" spread="157.55"/>
                    <measurement group_id="O4" value="-3.5" spread="56.09"/>
                    <measurement group_id="O5" value="-8.9" spread="61.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study drug administration (day 1) to follow-up visit (day 6 to 10)</time_frame>
      <desc>Analysis based on Safety population; all subjects who received any study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>0.25-mg Buprenorphine HCl Buccal Film, M2</title>
          <description>Buprenorphine HCl buccal film 0.25-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
        </group>
        <group group_id="E2">
          <title>0.5-mg Buprenorphine HCl Buccal Film, M2</title>
          <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 2, placebo buccal film, and placebo oral capsule</description>
        </group>
        <group group_id="E3">
          <title>0.5-mg Buprenorphine HCl Buccal Film, M1</title>
          <description>Buprenorphine HCl buccal film 0.5-mg modified formulation 1, placebo buccal film, and placebo oral capsule</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo oral capsule and 2 placebo buccal films</description>
        </group>
        <group group_id="E5">
          <title>Oxycodone 5 mg</title>
          <description>Oxycodone 5-mg oral capsule and 2 placebo buccal films</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Alveolar osteitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Coordinator</name_or_title>
      <organization>Endo Pharmaceuticals Inc.</organization>
      <email>clinicalsite.inquiries@endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

